$107 Million is the total value of Euclidean Capital LLC's 11 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 10.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INDA | New | ISHARES TRmsci india etf | $24,089,991 | – | 577,144 | +100.0% | 22.54% | – |
| ME | 23ANDME HOLDING CO | $22,125,144 | -24.5% | 10,243,122 | 0.0% | 20.70% | -23.9% | |
| PMVP | PMV PHARMACEUTICALS INC | $20,331,108 | -26.9% | 2,336,909 | 0.0% | 19.02% | -26.3% | |
| ALEC | ALECTOR INC | $9,053,652 | -2.4% | 980,894 | 0.0% | 8.47% | -1.7% | |
| RAPT | RAPT THERAPEUTICS INC | $8,571,420 | -17.7% | 432,900 | 0.0% | 8.02% | -17.1% | |
| FHTX | FOGHORN THERAPEUTICS INC | $8,046,845 | -25.6% | 1,261,261 | 0.0% | 7.53% | -25.1% | |
| ORIC | ORIC PHARMACEUTICALS INC | $4,403,070 | +84.1% | 747,550 | 0.0% | 4.12% | +85.5% | |
| FFBC | FIRST FINL BANCORP OH | $4,205,746 | +14.9% | 173,576 | 0.0% | 3.94% | +15.8% | |
| NGM | NGM BIOPHARMACEUTICALS INC | $3,748,303 | -61.6% | 746,674 | 0.0% | 3.51% | -61.3% | |
| TENAYA THERAPEUTICS INC | $1,840,567 | -30.7% | 915,705 | 0.0% | 1.72% | -30.2% | ||
| SURROZEN INC | $467,244 | -71.2% | 802,963 | 0.0% | 0.44% | -71.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
| FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
| NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
| ALECTOR INC | 12 | Q3 2023 | 11.5% |
| RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
| TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
| FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
| SURROZEN INC | 9 | Q3 2023 | 2.9% |
| 23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2023-12-01 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.